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ARTICLE
Performance of Plasma Adenosine as a Biomarker for 
Predicting Cardiovascular Risk
Trevor Simard1,2,3,†, Richard G. Jung1,2,†, Pietro Di Santo1, F. Daniel Ramirez1,4,5, Alisha Labinaz1, Chantal Gaudet1,  
Pouya Motazedian1,6, Simon Parlow1, Joanne Joseph1, Robert Moreland1, Jeffrey Marbach1, Paul Boland1, Steven Promislow1, 
Juan J. Russo1, Aun-Yeong Chong1, Derek So1, Michael Froeschl1, Michel Le May1 and Benjamin Hibbert1,2,*
Adenosine boasts promising preclinical and clinical data supporting a vital role in modulating vascular homeostasis. Its 
widespread use as a diagnostic and therapeutic agent have been limited by its short half-life and complex biology, though 
adenosine-modulators have shown promise in improving vascular healing. Moreover, circulating adenosine has shown prom-
ise in predicting cardiovascular (CV) events. We sought to delineate whether circulating plasma adenosine levels predict CV 
events in patients undergoing invasive assessment for coronary artery disease. Patients undergoing invasive angiography 
had clinical data prospectively recorded in the Cardiovascular and Percutaneous ClInical TriALs (CAPITAL) revascularization 
registry and blood samples collected in the CAPITAL Biobank from which adenosine levels were quantified. Tertile-based 
analysis was used to assess prediction of major adverse cardiovascular events (MACE; composite of death, myocardial 
infarction, unplanned revascularization, and cerebrovascular accident). Secondary analyses included MACE subgroups, 
clinical subgroups and adenosine levels. There were 1,815 patients undergoing angiography who had blood collected with 
adenosine quantified in 1,323. Of those quantified, 51.0% were revascularized and 7.3% experienced MACE in 12 months of 
follow-up. Tertile-based analysis failed to demonstrate any stratification of MACE rates (log rank, P = 0.83), when comparing 
low-to-middle (hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.68–1.78, P = 0.70) or low-to-high adenosine tertiles (HR 
0.95, 95% CI 0.56–1.57, P = 0.84). In adjusted analysis, adenosine similarly failed to predict MACE. Finally, adenosine did not 
predict outcomes in patients with acute coronary syndrome nor in those revascularized or treated medically. Plasma adeno-
sine levels do not predict subsequent CV outcomes or aid in patient risk stratification.
Adenosine serves as a crucial regulatory molecule in both 
intracellular and extracellular processes.1 Adenosine ho-
meostasis is closely regulated by an ongoing balance of 
production, degradation, and transport.2,3 Adenosine 
signaling is complex with four primary adenosine recep-
tors (1, 2A, 2B, and 3) facilitating extracellular signaling. 
These receptors are found on a multitude of vascular cells 
with differing responses based upon the cell and receptor 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Adenosine demonstrates promising preclinical and 
clinical data supporting its role as a vasculoprotective 
agent with limited data suggesting it may serve as a 
marker of clinical outcomes.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  We sought to definitively establish the role of circulat-
ing adenosine as a predictor of cardiovascular (CV) events 
in patients undergoing invasive assessment for coronary 
artery disease.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
✔  Systemic adenosine levels do not predict CV outcomes 
or aid in CV risk stratification.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔  Although risk stratification using systemic adenosine 
levels are not clinically useful, this does not preclude the 
potential of tissue-level adenosine differences nor the role 
of adenosine modulation for therapeutic benefit.
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subtypes. Accordingly, adenosine signaling has been impli-
cated in vascular homeostasis with considerable preclinical 
data supporting its role in vasculoprotection.1
Therapeutically, adenosine is limited by its relative insta-
bility and short half-life. As a hyperemic agent, it has found 
limited use in coronary flow assessment,4 although dipyr-
idamole is more commonly used to augment adenosine 
levels given its improved stability.5 Dedicated molecules 
specifically targeting adenosine receptors of interest are 
also in use to further optimize the intended vs. unintended 
effects of adenosine modulation.6 Indeed, adjunctive agents 
that augment adenosine levels have demonstrated promis-
ing results. Dipyridamole, augmenting adenosine through 
equilibrative nucleoside transporter-1 (ENT-1) inhibition, 
has demonstrated improved vascular patency and reduced 
restenosis in preclinical and clinical studies.1 Similarly, ci-
lostazol modestly augments adenosine levels in addition 
to cyclic adenosine monophosphate,7 yielding reduced 
restenosis following coronary stenting.8 Last, ticagrelor, a 
P2Y12 receptor inhibitor, demonstrates improved clinical 
outcomes aside from its antiplatelet effects proposed to be 
related to pleiotropic effects via augmentation of adenos-
ine9 (via ENT-1 inhibition)10 and possibly cyclic adenosine 
monophosphate.11 However, the precise impact of ticagrelor 
on circulating adenosine levels in clinical trials remains the 
subject of debate.12,13 Taken together, preclinical and clinical 
data supports that adenosine augmentation may portend 
vasculoprotective effects and thereby improve cardiovascu-
lar (CV) outcomes.
Diagnostically, circulating adenosine levels have not been 
widely adopted owing in part to the technical challenges with 
its quantification and notable biological variability.14 Despite 
this, small series have suggested a role for adenosine lev-
els in risk stratifying CV outcomes. Subjects with coronary 
artery disease (CAD) and genetically reduced adenosine 
deaminase (AMPD1) activity, theoretically increasing ade-
nosine levels, have demonstrated improved CV survival.15 
Similarly, we previously reported diminished adenosine 
levels in those with advanced age and obstructive CAD, 
although no association with established risk factors was 
noted.14 However, following revascularization, patients with 
AMPD1 did not demonstrate improved CV outcomes.16 This 
study was limited by its small size, nonconventional revas-
cularization strategies, and lack of difference in adenosine 
levels between the cohorts—supporting the challenges of 
utilizing adenosine as a biomarker.16 Patients post-revascu-
larization are at elevated risk of recurrent CV events,17 and 
exogenous adenosine has shown promise in improving vas-
cular healing in preclinical models.18 Given the uncertainty 
of the utility of adenosine as a biomarker, we sought to de-
termine whether circulating adenosine levels are predictive 
of future CV events in patients undergoing invasive assess-
ment for CAD.
METHODS
Adenosine sample collection and quantification
Adenosine samples were collected at the time of invasive 
angiography as previously described.14 Briefly, blood sam-
ples were collected via the plastic arterial access sheath 
(Terumo Medical, Somerset, NJ) or, rarely, if required by 
peripheral venipuncture. Samples were collected in pre-
filled Greiner BioOne Vacuette tubes containing 2  mL of 
ice-cold stop solution as reported.14 Hemolyzed samples 
were excluded.19 Samples were centrifuged and stored at 
−80°C to await processing. Samples were then processed 
via the Waters Oasis MCX (Mixed-mode, strong Cation-
eXchange) columns and transferred for high-performance 
liquid chromatography analysis on a Waters Alliance E2695 
separating module system with sample quantification by 
Waters 2489 UV/visible detector at 260 nM as previously 
reported.14 This methodology underwent thorough devel-
opment and validation with ongoing quality-of-care metrics 
to ensure robust adenosine quantification as described.14
Population and patient outcomes
The University of Ottawa Heart Institute provides sole re-
vascularization services to over 1.2 million people.20,21 The 
Cardiovascular and Percutaneous ClInical TriALs (CAPITAL) 
revascularization registry is a web-based registry that pro-
spectively indexes data on patients undergoing coronary 
angiography. Baseline demographics, CV risk factors and 
definitions have been previously described.14 Patients un-
dergo follow-up assessment in the year following their 
angiography where clinical outcomes in the year following 
revascularization are recorded in the registry. Outcomes 
were prospectively recorded by individuals blinded to ad-
enosine levels. Myocardial infarction (MI) was recorded 
according to the universal definition of MI or clinical di-
agnosis of MI by treating physicians.22 Repeat unplanned 
revascularization included patients undergoing repeat 
coronary intervention not planned following their index 
procedure and included both target vessel and non-target 
vessel revascularization. Death included both cardiac and 
noncardiac death. Stroke included both ischemic or hem-
orrhagic events as diagnosed by the treating neurologist or 
on cross-sectional imaging.
The primary outcome of interest was major adverse 
cardiovascular events (MACE) composed of death, MI, 
stroke, or unplanned revascularization at 1-year follow-up. 
Secondary outcomes of interest included individual MACE 
components and clinical subgroups.
The collection and use of blood samples in the CAPITAL 
Biobank was approved by the Ottawa Health Science 
Network Research Ethics Board (Protocol #20160516-01H) 
and informed consent was obtained from all patients for 
collection. The outcomes study assessment was approved 
by Ottawa Health Science Network Research Ethics Board 
(#20190224-01H and #20180562-01H) to evaluate clinical 
outcomes following revascularization.
Statistical analysis
Data are reported as mean  ±  SD, median  ±  interquartile 
range, or number and percentage (%) where appropriate. 
Plasma adenosine levels were compared using Mann–
Whitney U tests. Plasma adenosine levels were categorized 
into tertiles (33rd and 67th percentiles) and Kaplan–Meier 
plots generated to assess event distributions with compari-
son by log rank tests. Subsequent Cox proportional-hazard 
models were then used to determine hazard ratios (HRs) 
and 95% confidence intervals (CIs). Multivariable Cox 
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proportional-hazards model was also performed incor-
porating variables known to impact adenosine levels and 
post-revascularization MACE, including age (years), sex, 
diabetes mellitus type 2, hypertension, dyslipidemia, CAD, 
acute coronary syndrome, and revascularization, as doc-
umented previously and highlighted in univariate analysis 
(Table S1).14,23 We estimated an incidence rate of 9.5% and 
15.5% (effect size of 60%) between the lowest and high-
est adenosine tertiles with an α = 0.05 and β = 0.20 which 
yielded a sample size of 476 per tertile for a total sample 
of 1,428 subjects. All statistical analyses were completed 
using SAS version 9.4 (SAS Institute, Cary, NC). All figures 
were created using GraphPad Prism version 8 (GraphPad 




During the study period, 1,815 patients underwent angi-
ography and had blood collected in the CAPITAL Biobank 
for further analysis with 1-year follow-up completed. Within 
the collected samples, 1,323 had adenosine levels quanti-
fied from the time of index angiography and were included 
in our analysis. Of the 1,323 patients included, 675 (51.0%) 
underwent revascularization by either percutaneous coro-
nary intervention (PCI; 70.8%) or coronary artery bypass 
grafting (CABG; 28.7%) or both (0.4%). Medical therapy was 
pursued in 648 patients (49.0%) with 64.5% having obstruc-
tive CAD and 35.5% have no obstructive CAD at the time of 
angiography (Figure 1). Mean age was 66.8 ± 11.6 years, 
29.3% were women, risk factors included 65.2% with hy-
pertension, 61.1% with dyslipidemia, 30.5% with diabetes, 
18.1% active smokers, and 14.9% with a family history 
of CAD. Indications for angiography included 59.7% with 
acute coronary syndrome (ACS) and 37.7% with stable 
CAD. Patients had a history of PCI (27.7%), MI (23.3%), 
CABG (6.5%), peripheral artery disease (6.7%), and cere-
brovascular accident (CVA; 6.5%). Medications at the time 
of angiography included aminosalicylic acid 90.9%), P2Y12 
(89.4%), angiotensin-converting enzyme/angiotensin re-
ceptor blocker; 53.5%), beta-blocker (59.2%), and statin 
(80.9%; Table 1). Adenosine values were stratified accord-
ing tertile (i) 0–33rd (low adenosine, n = 436) with a cutoff 
of 693.2 nM; (ii) 34–67th (middle adenosine, n = 451) with a 
cutoff level of 902.9 nM; and (iii) 68–100th (high adenosine, 
n = 436) with a cutoff level of 1141.9 nM with baseline char-
acteristics stratified by tertiles (Table 1).
Patient outcomes
Patient outcomes were assessed at 1 year from their revas-
cularization procedure, as previously described.14 MACE 
occurred in 7.3% of patients at 1  year. When stratifying 
outcomes by adenosine tertiles we noted no significant 
differences in MACE rates between the tertiles (log rank 
P = 0.83). Similarly, no differences in HRs were noted when 
comparing the low to middle (HR 1.10, 95% CI 0.68–1.78, 
P = 0.70) or low to high adenosine tertiles (HR 0.95, 95% CI 
0.56–1.57, P = 0.84; Figure 2a).
Secondary outcome analysis of the individual MACE com-
ponents similarly revealed no changes among the subgroups 
(Figure 2b–e): death (log rank P = 0.95) and low vs middle 
(HR 1.02, 95% CI 0.55–1.92, P = 0.94) or low to high ade-
nosine tertiles (HR 0.93, 95% CI 0.49–1.77, P = 0.82); MI (log 
rank P = 0.95), low vs. middle (HR 1.17, 95% CI 0.36–3.83, 
P = 0.80) or low to high adenosine tertiles (HR 0.98, 95% CI 
0.28–3.38, P = 0.98); or unplanned revascularization (log rank 
P = 0.49); and low vs. middle (HR 1.01, 95% CI 0.53–1.90, 
P = 0.98) or low vs. high adenosine tertiles (HR 0.69, 95% 
CI 0.34–1.39, P  =  0.29). When assessing CVA individually 
there was a noted difference with CVA stratified by adenos-
ine tertiles (log rank P = 0.03), with no differences observed 
between low vs. middle (HR 4.37, 95% CI 0.95–20.23, 
P = 0.059) or low vs. high adenosine tertiles (HR 0.97, 95% CI 
0.14–6.89, P = 0.98; Figure 2c). Adjusted analyses for age, 
ACS, diabetes mellitus type 2, sex, CAD, revascularization, 
hypertension, and dyslipidemia did not change the observed 
trends with no difference seen in MACE between low vs. 
middle (HR 1.11, 95% CI 0.68–1.80, P = 0.68) or low vs. high 
adenosine tertiles (HR 1.05, 95% CI 0.63–1.74, P = 0.85), nor 
in unplanned revascularization between low vs. middle (HR 
1.06, 95% CI 0.56–2.01, P = 0.86) or low vs. high adenosine 
tertiles (HR 0.70, 95% CI, 0.34–1.42, P = 0.32; Table 2).
Figure 1 Patient flow diagram. CABG, coronary artery bypass grafting; CAD, coronary artery disease; CAPITAL, Cardiovascular and 
Percutaneous Intervention Trials; PCI, percutaneous coronary intervention.
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Subgroup analyses were performed to further assess 
three cohorts of patients—demonstrating no significant dif-
ferences between adenosine tertiles in MACE or unplanned 
revascularization: (i) medical therapy for obstructive CAD 
(Figure S1)—MACE (log rank P  =  0.16) and low vs. mid-
dle (HR 0.68, 95% CI 0.36–1.26, P = 0.22) or low vs. high 
adenosine tertiles (HR 0.54, 95% CI 0.27–1.06, P = 0.07), 
and unplanned revascularization (log rank P  =  0.77) and 
low vs. middle (HR 1.02, 95% CI 0.41–2.58, P  =  0.96) or 
low vs. high adenosine tertiles (HR 0.72, 95% CI 0.26–2.03, 
P  =  0.54); (ii) revascularization cohort (Figure S2)—MACE 
(log rank P  =  0.16) and low vs. middle (HR 1.89, 95% CI 
0.75–4.74, P = 0.17) or low vs. high adenosine tertiles (HR 
2.34, 95% CI 0.96–5.68, P = 0.06) and unplanned revascu-
larization (log rank P = 0.86) and low vs. middle (HR 0.92, 
95% CI 0.32–2.08, P = 0.86) or low vs. high adenosine ter-
tiles (HR 0.79, 95% CI 0.31–2.00, P  = 0.62); and (iii) ACS 
cohort (Figure S3)—MACE (log rank P = 0.32) and low vs. 
middle (HR 0.57, 95% CI 0.27–1.21, P = 0.14) or low vs. high 
adenosine tertiles (HR 0.74, 95% CI 0.37–1.50, P  =  0.41) 




Number 1323 436 451 436
Age, mean ± SD 66.8 11.6 67.0 11.4 67.3 11.8 66.2 11.6
Sex, female, n % 387 29.3 112 25.7 144 31.9 131 30.0
Hypertension, n % 863 65.2 287 65.8 281 62.3 295 67.7
Dyslipidemia, n % 808 61.1 266 61.0 277 61.4 265 60.8
Diabetes, n %
Type I 8 0.6 4 0.9 1 0.2 3 0.7
Type II 396 29.9 132 30.3 116 25.7 148 33.9
Diet 24 1.8 8 1.8 7 1.6 9 2.1
Oral hypoglycemic 
agents
266 20.1 85 19.5 82 18.2 99 22.7
Insulin 106 8.0 39 8.9 27 6.0 40 9.2
Smoking, n %
Never 765 57.8 261 59.9 253 56.1 251 57.6
Remote 319 24.1 95 21.8 113 25.1 111 25.5
Active 239 18.1 80 18.3 85 18.8 74 17.0
Family history of CAD, 
n %
197 14.9 71 16.3 56 12.4 70 16.1
Indication for angiography, n %
ACS 790 59.7 176 40.4 176 39.0 181 41.5
Staged PCI 150 11.3 54 12.4 52 11.5 44 10.1
Stable CAD 499 37.7 174 39.9 173 38.4 152 34.9
Atrial fibrillation, n % 137 10.4 38 8.7 47 10.4 52 11.9
Medical history, n %
PCI 366 27.7 124 28.4 119 26.4 123 28.2
MI 308 23.3 107 24.5 92 20.4 109 25.0
CABG 86 6.5 26 6.0 28 6.2 32 7.3
PAD 89 6.7 25 5.7 30 6.7 34 7.8
CVA 86 6.5 24 5.5 23 5.1 39 8.9
Bleed 23 1.7 9 2.1 4 0.9 10 2.3
Heart failure 100 7.6 33 7.6 25 5.5 42 9.6
Medications, n %
ASA 1203 90.9 404 92.7 404 89.6 395 90.6
P2Y12 1183 89.4 401 92.0 395 87.6 387 88.8
ACEi/ARB 708 53.5 224 51.4 242 53.7 242 55.5
Beta-blocker 783 59.2 255 58.5 273 60.5 255 58.5
Calcium channel 
blocker
185 14.0 62 14.2 62 13.7 61 14.0
Statin 1070 80.9 364 83.5 360 79.8 346 79.4
Revascularized, n % 675 51.0 238 54.6 214 47.5 223 51.1
ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ACS, acute coronary syndrome; ASA, acetylsalicylic acid; CABG, coro-
nary artery bypass grafting; CAD, coronary artery disease; CVA, cardiovascular accident; MI, myocardial infarction; PAD, peripheral artery disease; PCI, 
percutaneous coronary intervention.
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and unplanned revascularization (log rank P  =  0.96) and 
low vs. middle (HR 1.12, 95% CI 0.45–2.75, P  =  0.81) or 
low vs. high adenosine tertiles (HR 1.01, 95% CI 0.40–2.55, 
P = 0.98). Moreover, from a clinical perspective, those who 
experienced MACE were more likely to be older (72.4 ± 11.5 
vs. 66.1 ± 11.4 years, P < 0.0001) and have hypertension 
(73.4% vs. 64.1%, P = 0.02), dyslipidemia (72.2% vs. 59.6%, 
P = 0.002), diabetes (46.2% vs 27.7%, P < 0.0001), and a 
history of MI (30.4% vs. 22.3%, P  =  0.02), CABG (10.8% 
vs. 5.9%, P = 0.02), and peripheral artery disease (11.4% 
vs. 6.1%, P  =  0.01). Patients with MACE were less likely 
to present as stable CAD (29.1% vs. 38.9%, P = 0.02) and 
less likely to undergo revascularization (39.2% vs. 52.6%, 
P = 0.002; Table S1).
Finally, we evaluated adenosine values within each out-
come cohort with no significant differences noted in any 
comparison (Figure 3): (i) MACE—absent (n  =  1,227) vs. 
present (n  =  96, 902.2  nM (621.4–1,292.3  nM) vs. 914.2 
585.0–1,324.5 nM), P = 0.86); (ii) death—absent (n = 1,266) 
vs. present (n  =  57, 904.1  nM (621.4–1,285.2  nM] vs. 
857.0  nM (540.8–1,418.7  nM), P  =  0.68); (iii) MI—absent 
(n = 1307) vs. present (n = 16, 902.8 nM (619.9–1,292.3 nM) 
vs. 838.7 nM (562.8–1,294.9 nM), P = 0.77); (iv) CVA—absent 
(n = 1,310) vs. present (n = 13; 902.2 nM (619.1–1,295.7 nM) 
Figure 2 Adenosine levels and cardiovascular outcomes. (a) Major adverse cardiac events (MACE) including death, cerebrovascular 
accident (CVA), myocardial infarction (MI), and unplanned revascularization did not demonstrate any difference between middle or 
high adenosine tertiles. Similar trends were observed when analyzing by subgroups with no differences between tertiles noted for (b) 
death, (d) MI, and (e) unplanned revascularization. (c) CVA demonstrated higher incidence of stroke in the middle adenosine tertile. 
Adenosine levels stratified into tertiles (0–33rd, 34–66th, and 67–100th) for analysis. Kaplan–Meier curves generated and compared 
via log rank with subsequent unadjusted hazard ratios (HRs) compared by Cox proportional hazards model. P < 0.05 was defined as 
statistically significant. ADO, adenosine levels; CI, confidence interval.
Table 2 Clinical outcomes predicted by plasma adenosine levels
MACE Unplanned revascularization
Event rates (%) HR (95% CI) P value Event rates (%) HR (95% CI) P value
Low adenosine 7.1 – 4.4 –
Unadjusted analysis (relative to low adenosine)
Middle adenosine 7.8 1.10 (0.68–1.78) 0.70 4.2 1.01 (0.53–1.90) 0.98
High adenosine 6.9 0.95 (0.56–1.57) 0.84 3.0 0.69 (0.34–1.39) 0.29
Adjusted analysis (relative to low adenosine)a
Middle adenosine 7.8 1.11 (0.68–1.80) 0.68 4.2 1.06 (0.56–2.01) 0.86
High adenosine 6.9 1.05 (0.63–1.74) 0.85 3.0 0.70 (0.34–1.42) 0.32
CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiac event.
aAdjusted for age (years), sex, type 2 diabetes, hypertension, dyslipidemia, coronary artery disease, acute coronary syndrome, and revascularization.
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vs. 953.2 nM (802.0–1,007.3 nM), P = 0.82); (v) unplanned 
revascularization—absent (n  =  1,272) vs. present (n  =  51, 
904.3 nM (619.9–1,297.9 nM) vs. 770.7 nM (615.4–1,144.8), 
P = 0.26).
DISCUSSION
In the current study, we sought to evaluate the ability of 
plasma adenosine levels to risk stratify patients and pre-
dict MACE. Contrary to our hypothesis, adenosine levels 
were not found to predict MACE rates at 1  year of fol-
low-up, nor did it predict any of the individual components. 
Multivariable adjustment for factors known to influence out-
comes and adenosine levels similarly did not demonstrate 
a clear role of adenosine for risk stratifying patients at the 
time of invasive angiography. Hence, this study does not 
support the use of plasma adenosine in risk stratification of 
cardiac patients for 1 year events.
Prior to our analysis, adenosine’s role as a predictor of 
CV outcomes was inconclusive. Individuals with genetic 
mutations (AMPD1) leading to reduced adenosine deam-
inase activity provide a unique perspective on the role of 
adenosine in CV outcomes. Elevated adenosine levels have 
been noted in patients with heart failure (HF) previously, 
supporting a compensatory role as a counter-regulatory 
molecule in response to rising catecholamine levels 
endemic to patients with HF.24 Therapeutically, dipyrida-
mole-induced adenosine augmentation was suggested 
to improve HF severity.25 Moreover, less-adverse out-
comes have been noted in patients with HF with AMPD1 
mutations; although adenosine levels were not assessed, 
limiting discernment as to whether circulating or tissue 
adenosine differences led to the observed changes.26,27 
Indeed, AMPD1 is most active in the skeletal muscle, 
suggesting tissue levels may be more directly affected.28 
Moreover, when 367 patients with obstructive CAD were 
stratified by AMPD1 status, they demonstrated improved 
CV outcomes, although adenosine levels were not quanti-
fied.15 However, 161 patients undergoing revascularization 
(PCI and CABG) did not demonstrate differential circulating 
adenosine levels by AMPD1 status, nor did AMPD1 status 
predict CV outcomes, suggesting alternative pathways for 
its observed effects.16 Indeed, these discrepant results re-
flect an incomplete understanding of adenosine biology, in 
that the observed outcome effects may actually be driven 
by modification of local cardiac/vascular adenosine levels 
with systemic adenosine levels providing a relatively minor 
role as supported by work in patients with HF.16,29 Similarly, 
our findings may suggest that local adenosine levels may 
be more relevant and predictive of vascular healing. While 
Figure 3 Comparison of adenosine levels across cardiovascular outcome groups. Circulating adenosine values presented according 
to each cohort with no significant differences noted among: (a) MACE—absent (n = 1,165) vs. present (n = 158, 902.8 nM (619.9–
1,285.2 nM) vs. 904.0 (616.7–1,295.7 nM), P = 0.99). (b) Death—absent (n = 1,255) vs. present (n = 68, 903.3 nM (621.4–1,283.1 nM) vs. 
897.8 nM (543.9–1,458.1 nM), P = 0.99). (c) MI—absent (n = 1,293) vs. present (n = 30, 902.8 nM (619.9–1,292.3 nM) vs. 907.0 nM (709.2–
1,341.0 nM), P = 0.63). (d) CVA—absent (n = 1,294) vs. present (n = 29, 897.6 nM (618.3–1,292.3 nM] vs. 970.0 nM (837.0–1,256.7 nM), 
P = 0.25). (e) Unplanned revascularization—absent (n = 1,263) vs. present (n = 60, 905.7 nM (619.6–1,302.2 nM) vs. 789.8 nM (616.0–
1,127.2), P = 0.15). Data was presented as median (interquartile range (IQR)) and compared using Mann–Whitney U test. P < 0.05 was 
defined as statistically significant. CVA, cerebrovascular accident; MACE, major adverse cardiac events; MI, myocardial infarction.
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direct coronary sampling has demonstrated reduced local 
adenosine levels post-PCI,30 the technical barriers of this 
approach would preclude meaningful adoption as a clini-
cal tool.
Whereas circulating adenosine levels may not predict 
future events, this does not exclude adenosine as a vi-
able therapeutic target, particularly when considering 
its tissue-level characteristics. As discussed, numerous 
agents known to modulate adenosine have shown fa-
vorable impacts on vascular healing and cardiovascular 
outcomes, including dipyridamole,1 cilostazol,7,8 and ti-
cagrelor.9 Although all of these agents have demonstrated 
favorable impact on clinical outcomes, the mechanism of 
action may be on local rather than circulating adenosine 
levels. Dipyridamole is commonly used in i.v. formulation 
leading to transient peaks in central adenosine levels31 
lessening with repeated stimuli,32 whereas sustained oral 
administration up to 5 days demonstrated early changes 
in circulating adenosine, lessening after 48  hours.33 
However, dipyridamole is known to more potently inhibit 
ENT-1 than ticagrelor, prolonging detectable levels of ade-
nosine following adenosine administration in the presence 
of both agents.34 Although ticagrelor has been shown 
to augment circulating adenosine in the setting of ACS, 
other studies have failed to consistently demonstrate this 
effect.12,13 Taken together, these findings suggest that 
although therapeutic modulation of adenosine may rep-
resent a viable target, the effect on adenosine levels may 
occur transiently at a systemic level, with more sustained 
augmentation locally. Moreover, adenosine receptor lev-
els have been shown to dynamically respond to changes 
in adenosine levels, reflecting yet another pathway by 
which vasculoprotective effects are mediated, while 
not appreciably impacting systemic adenosine levels.35 
Indeed, using systemic adenosine levels as a target di-
agnostically or therapeutically is challenged by its innate 
properties, variations between local and systemic levels 
and the complex homeostatic mechanisms regulating 
adenosine levels. Hence, although monitoring adenosine 
levels may not provide prognostication abilities, modulat-
ing adenosine biology still carries significant promise as 
a therapeutic approach and remains the focus of ongoing 
investigation.
Our study is not without limitations. First, our population 
is heterogenous with a variety of indications for invasive 
angiography and differential revascularization strategies, 
although assessment of these various subgroups similarly 
failed to demonstrate prognostic effects. Second, our fol-
low-up period was limited to 1 year and we cannot rule out 
the possibility that adenosine may predict longer term out-
comes; however, we are unable to determine this within the 
confines of the current study. Finally, systemic quantification 
of adenosine levels is subject to biological and analytical 
variation, which may impact levels quantified.14
CONCLUSION
Systemic adenosine levels are not predictive of CV events at 
one year in patients undergoing angiography. Although ther-
apeutic targeting of adenosine and associated pathways 
may yet be beneficial, risk stratification using this molecule 
is not clinically useful.
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